FDA approves monthly subcutaneous olanzapine LAI Weltruza, expanding schizophrenia treatment options and renewing debate on making long-acting injectables routine.
|Videos|June 10, 2021
Talking to Patients About Transcranial Magnetic Stimulation
Author(s)Abhijit Ramanujam, MD
What are the clinical benefits of TMS? How can you talk to your patients about this option?
Advertisement
Abhijit Ramanujam, MD, introduces Transcranial Magnetic Stimulation (TMS) as an option for treating your patients with hard-to-treat depression.
Dr Ramanujam is a practicing child and adolescent psychiatrist in Sacramento, California, and the Regional Medical Director of
Advertisement
Related to this article
Athletes can feel the relief a substance gives them long before they can see what it costs. A composite case of cannabis use in a track athlete shows how to assess both.
How past “untreatable” labels mislead psychiatry—and why measurement-informed care and difficult-to-treat depression replace today’s treatment-resistant mindset.
There is a question older than medicine, and perhaps older than philosophy, that psychiatry has largely avoided: What makes us human?
APSARD is preparing US adult ADHD guidelines, delivering long-awaited screening, diagnosis, and treatment recommendations as experts discuss the upcoming release.
Review top pipeline updates from last week.
Rethink “treatment-resistant depression” by adopting difficult-to-treat depression, verifying adequate trials, and stratifying drivers like trauma and inflammation to improve outcomes.
Once-monthly subcutaneous olanzapine LAI requires no loading doses, oral supplementation, or post-injection monitoring, based on phase 3 SOLARIS data.
Advertisement
Advertisement
Trending on Psychiatric Times
1
The New, Impending Adult ADHD Guidelines
2
Moving Away From Treatment-Resistant Depression and Toward Difficult-to-Treat Depression
3
Reframing “Treatment-Resistant” as “Difficult-To-Treat”
4
Relief Is Not Free: A Case Study of Athlete Cannabis Use
5